S-HIO has received consulting fees from Pfizer, Lilly, Janssen, Daiichi Sankyo, BMS, AnHeart Therapeutics, J Inst Bio, Bayer, Merus, BluePrint Medicines, Takeda, and Roche; honoraria for lectures or presentations from Pfizer, Janssen, and Caris Life Science; institutional clinical research funding from Daiichi Sankyo, Roche, Nuvalent, Pfizer, Mirati Therapeutics, Revolution Medicines, and ERACAS; continuing medical education funding from OncLive, HMP Education, and Dava Oncology; and payment from Elevation Oncology and stock options from AnHeart Therapeutics for scientific advisory board membership; and has stock ownership in MBrace Therapeutics, BlossomHill Therapeutics, Nuvalent, Turning Point Therapeutics, Elevation Oncology, and Lilly. JBL declares no competing interests.